/
AKTS
$23.90+$0.11 (+0.46%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$1.3B
55M shares
52-week range
$14.72 – $34.19
47% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Change+$15.50
Aktis Oncology, Inc. Common stock
Aktis Oncology Inc is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company specializes in developing targeted alpha radiopharmaceuticals for solid tumors such as breast, lung, colorectal, bladder, and liver cancers. Its pipeline products include AKY-1189 and AKY-2519, focusing on solid tumors. The company has one operating and reportable segment focused on the research and development of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers. The company generates revenue from Collaboration agreement.
www.aktisoncology.com- Employees
- 79
- IPO / List date
- Jan 9, 2026
- HQ
- BOSTON, MA
Held by traders on TradeandTell
No one on the platform currently holds AKTS.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in AKTS as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2015-04-24 | 1.094891-for-1 |
Recent trades on TradeandTell
No one on the platform has traded AKTS yet.
